GlassScriptPhysician profile
Chandler E Padgett
NPI 1679129993
$2,922.68
in general payments reported to CMS, 2019-2025
21 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $158 · 2022: $888 · 2023: $564 · 2024: $890 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,876.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $340.12 | 2023-2024 | Farxiga |
| Neurocrine Biosciences, INC. | $249.99 | 2022 | |
| Sobi, INC | $218.00 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $201.42 | 2025 | |
| Galderma Laboratories, L.P. | $182.55 | 2023-2025 | |
| Merz North America, INC. | $166.49 | 2022-2024 | |
| Daiichi Sankyo INC. | $160.26 | 2022-2025 | Enhertu |
| Incyte Corporation | $146.37 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $131.47 | 2024 | Monoferric |
| Axsome Therapeutics, INC. | $124.37 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $124.09 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $118.74 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $118.04 | 2022 | |
| Dexcom, INC. | $115.19 | 2024 | Dexcom G7 Gss (161) |
| Neurelis, INC. | $111.25 | 2023 | Valtoco |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $87.69 | 2024 | |
| Genzyme Corporation | $84.46 | 2022 | |
| Dova Pharmaceuticals | $80.71 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $73.08 | 2022 | |
| Janssen Pharmaceuticals, INC | $55.90 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.49 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandler Padgett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.